Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Significant Increase in Short Interest

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 228,200 shares, an increase of 332.2% from the February 13th total of 52,800 shares. Based on an average daily volume of 354,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 4.4% of the company’s shares are sold short.

Alzamend Neuro Stock Down 1.8 %

Alzamend Neuro stock opened at $0.68 on Friday. Alzamend Neuro has a one year low of $0.64 and a one year high of $15.06. The business’s fifty day moving average is $1.02 and its 200 day moving average is $1.38.

Alzamend Neuro (NASDAQ:ALZN) last announced its earnings results on Monday, March 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.10. As a group, research analysts anticipate that Alzamend Neuro will post -1.68 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets decreased their price objective on Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating for the company in a report on Monday, December 16th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alzamend Neuro stock. Geode Capital Management LLC acquired a new position in Alzamend Neuro, Inc. (NASDAQ:ALZN) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 33,540 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned 0.62% of Alzamend Neuro as of its most recent SEC filing. Institutional investors own 49.61% of the company’s stock.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.